# Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

> **NCT07486206** · NA · RECRUITING · sponsor: **Hospital de Granollers** · enrollment: 152 (estimated)

## Conditions studied

- Interstitial Lung Disease (ILD)
- Fibrotic Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis (IPF)
- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

## Interventions

- **OTHER:** Standard ILD Follow-Up Pathway
- **OTHER:** Optimized One-Day ILD Follow-Up Circuit

## Key facts

- **NCT ID:** NCT07486206
- **Lead sponsor:** Hospital de Granollers
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486206, "Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07486206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*